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The P2RX7 gene is comprised of 13 coding exons. 
Transcription 
The full length transcript is 3135 bp long and 10 





The protein has 595 residues amino acids and 
compromises a 69 kDa calculated molecular weight. 
However, N-glycosylation in the extracellular loop 
increases the size of the P2X7 receptor to about 75-85 
kDa; the protein is composed successively (from the N- 
to the C-terminus) by:  
- 25 amino acid intracellular N-terminus 
- 21 amino acid first transmembrane domain 
- 288 amino acid extracellular loop 
- 21 amino acid second transmembrane domain 
- 240 amino acid intracellular C-terminal region 
Expression 
In a wide variety of tissues including heart, liver, 
pancreas, thymus, skeletal muscle and brain, although 
in brain the expression is mainly restricted to microglia. 
It also has relevant expression and function in immune 
cells (mainly in antigen presenting cells, such as 
monocytes, macrophages and dendritic cells). 
Localisation 
Mainly is found in the plasma membrane, however it 
also can be found in intracellular membrane 
compartments while trafficking to the plasma 
membrane. 
Function 
Acts as a ligand gated ion channel, sensing high 
concentration of extracellular ATP. Responsible for 
ATP-dependent activation and release of 
proinflammatory cytokines of the interleukin-1 family, 
mainly interleukin-1beta, interleukin-18 and 
interleukin-1alpha, playing a pivotal role in 
inflammatory responses. Prolonged stimulation of the 
P2X7 receptor can lead to plasma membrane bleb 
formation, opening of pannexin-1 dependent membrane 
pores and eventual cell death. 
Homology 
With other P2X receptors, with the higher homology 
with P2RX4. Excluding the unique C-terminal domain, 
homology is 39-49% with other P2X receptors. 
Mutations 
Germinal 
The human P2X7 receptor gene is highly polymorphic 
and more then 260 SNP have been described, only four 
loss-of-function and one gain-of-function SNP have 
been described to date:  
- Loss of protein function: 
946 G to A (Arg-307 to Gln)  
1068 G to A (Ala-348 to Thr)  
1513 A to C (Glu-496 to Ala)  
1729 T to A (Ile-568 to Asp)  
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- Gain of protein function: 
489 C to T (His-155 to Tyr) 
Somatic 
Not known in human. 
Implicated in 
Extrapulmonary tuberculosis 
Note: The P2RX7 1513C allele has been strongly 
associated with extrapulmonary tuberculosis. The allele 
was associated with a reduced killing of 
Mycobacterium tuberculosis by macrophages. 
Chronic lymphoid leukemia (CLL) 
Note: The 1513C allele of P2RX7 has been associated 
with the clinical course of patients affected by chronic 
lymphocytic leukemia (CLL). 
There is a possible role for the P2X7 receptor in the 
susceptibility to familial CLL or, alternately, the 1513C 
allele may be in linkage disequilibrium with a nearby 
susceptibility gene. 
Various cancers, including breast 
cancer, prostate cancer, papillary 
thyroid cancer and neuroblastoma 
Note: P2X7 receptor is overexpressed in a variety of 
cancers (see above). A detailed understanding of the 
mechanistic contribution mediated by P2RX7 has yet to 
be established. However, there is substantial evidence 
that the P2X7 receptor may mediate cell survival and 
growth by increasing the efficiency of oxidative 
phosphorylation and total intracellular ATP stores. 
Finally it has been proposed that the P2X7 receptor 
may be a candidate marker of papillary thyroid cancer. 
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